The coronavirus outbreak has tightened its grip and it has infected over 5.6 million people and killed 352,235 people globally and still, there is no vaccine for it. The scientists from the Israeli Institute for Biological Research (IIBR) claim that the two drugs that are used to treat Gaucher’s disease –a genetic disorder will be effective against the treatment for COVID-19 infection.
As per the study conducted by the Defence ministry- run IIBR, the existing drug Cerdelga and another drug which is in the stage of approval can act as an antiviral therapeutic against the SARS-Cov-2 virus which causes COVID-19 disease, as well as other viruses.
- G20 Fiscal Packages to Fight the Coronavirus Crisis Exceeds $4, 68 Trillion
- ICMR Removes Price Cap of Rs 4,500 for Coronavirus Tests; States can Now Decide the Price
According to Israeli study findings published in the bioRxiv preprint website, combining both the medications will lead to a significant decrease in the capacity of COVID -19 and destruct the infected cell. This decrease in virus replication and prevents further cells from getting infected; they carried out the study in cell culture.
In the publication by IIBR on page 24, the researchers said, “Infection with SARS-CoV-2 reduced cell visibility to 40% in the untreated cell. However, when treated with Cerdelga and Remdesivir, cell visibility was increased to between 75% and 100% demonstrating that they have an antiviral effect on the SARS-CoV-2 Clinical isolate in vitro”.
Now the scientists are testing the drugs on the animals to check if they get the same result or not.
Both the drugs were also effective in the treatment of Neuroinvasive Sindbis Virus (SVNI), West Nile Virus, and Influenza A-Virus.
Speaking on the research the Defence Minister said that- the results indicate the drugs and their potential in treating various viral diseases, including the further outbreak of new viruses if they secure clinical approval.
Benjamin Netanyahu, Israel Prime Minister, Last month said that IIBR has made significant progress in creating a COVID-19 vaccine prototype and the preparations for testing on animals are underway.